What РАГВИЗАКС Treats: Main Uses and Benefits

The primary role of РАГВИЗАКС is a disease-modifying therapeutic approach for patients with seasonal allergies, relevant for the long-term therapeutic approach to seasonal allergies rather than just immediate symptom relief.

This medication is generally applied in the context of disease-modifying treatment for grass pollen-induced allergic rhinitis and conjunctivitis in adults and children (5 years or older) who have clinically relevant symptoms.

---

Therapeutic Focus and Benefit

This treatment is applied across therapeutic domains where the patient experiences conditions associated with acute or disruptive episodes of allergic rhinoconjunctivitis. It is used for managing symptom clusters that may become intense or disruptive during the grass pollen season, including prominent rhinitis symptoms (like persistent sneezing and nasal congestion) and ocular symptoms (such as itchy, watery eyes).

The medication may assist with the goal of minimizing the reliance on symptomatic relief, helping maintain a sense of stability when symptoms are more noticeable, and contributes to improved comfort during periods of heightened symptoms.

“The primary goal of this therapy is not quick symptom suppression but rather a reduction in the severity of symptoms over time.”

---

QuickFact: Relief for Disruptive Seasonal Symptoms

This treatment is generally applied for long-term use in patients whose moderate to severe grass allergy symptoms interfere with daily functioning during the peak pollen period.

Regulatory References

1. High Authority of Health (France) Transparency Committee Opinion on Grazax

Eligibility Profile: Who Can and Cannot Use РАГВИЗАКС?

This medication is officially approved for use in adults and children 5 years of age and older who have confirmed grass pollen-induced allergic rhinitis, with or without conjunctivitis, according to governmental regulatory labeling. The approved population is strictly defined by specific age and diagnostic criteria, with use in children under 5 years being not recommended as safety and efficacy have not been established.

Absolute Contraindications

РАГВИЗАКС must not be used by patients with severe, unstable, or uncontrolled asthma, or a history of eosinophilic esophagitis. Use is also prohibited for individuals with known hypersensitivity to any excipients or those with malignancy or systemic diseases that affect the immune system.

Conditional Restrictions

Treatment initiation is not recommended during pregnancy or lactation. Additionally, the medicine must be temporarily interrupted if the patient develops severe oral inflammation or has recent dental procedures, resuming only after the area has fully healed. Clinical experience is limited in individuals 65 years of age and older.

The official interaction profile for РАГВИЗАКС (Allergoids Grass Pollen) is based on pharmacodynamic considerations and administration constraints, as the allergen extract does not engage in typical metabolic enzyme (CYP) or transporter-mediated pharmacokinetic interactions.

Pharmacodynamic Interactions

Interactions are mainly related to two contexts:

• Emergency Epinephrine: Co-administration with certain medicinal products may alter the effectiveness of emergency epinephrine (adrenaline) used to treat a potential severe allergic reaction. Beta-blockers may reduce its effects, while substances like Tricyclic Antidepressants, MAOIs, Levothyroxine, and certain antihistamines may potentiate its adverse effects. Patients receiving epinephrine while on cardiac glycosides or diuretics should be observed for cardiac arrhythmias.
• Symptomatic Anti-allergic Agents: Concomitant use of symptomatic allergy treatments, such as antihistamines, corticosteroids, or mast cell stabilizers, is officially noted to potentially increase the patient’s tolerance level to the immunotherapy.

Administration-Timing and Procedural Constraints

Treatment interruption is required under specific conditions affecting the sublingual area. Regulatory documents mandate that treatment must be temporarily interrupted to allow complete healing following dental extraction, oral surgery, or in the presence of oral inflammation or mouth ulcers.

Furthermore, to ensure proper absorption of the sublingual tablet, food or drink must be avoided for five minutes after the administration of the medicine.

The mechanism of РАГВИЗАКС is a targeted biological process called Allergen-Specific Immunotherapy (AIT), which aims to alter the immune response to grass pollen through the induction of immunological tolerance. The process involves changes to adaptive immune cells and operates independently of mechanisms designed for acute relief.

Redirection of Immune Signaling via T Cell Re-education

The primary action begins when the modified grass pollen (allergoid) is absorbed by Antigen-Presenting Cells (APCs) in the oral mucosa. This uptake triggers the proliferation of Regulatory T cells ( T reg), which actively release suppressive cytokines ( IL-10 and TGF-beta). This mechanism contributes to an alteration of the systemic immune response by downregulating the activity of the pro-allergic T Helper 2 ( T H2) cells.

Production of Molecular IgG4 Antibodies

As the immune response is modulated, the mechanism promotes Isotype Switching in B cells, shifting production from IgE to non-inflammatory IgG4 antibodies. These IgG4 antibodies bind to grass pollen molecules, preventing their access to IgE bound to effector cells. This limitation of IgE cross-linking reduces the reactivity of inflammatory cells (Mast cells and Basophils).

Specificity and Time-Dependent Constraint

The mechanism is intrinsically limited by the requirement for adaptive immune remodeling, reflecting the requirement for gradual biological adaptation over sustained exposure, rather than immediate engagement. Furthermore, the action is strictly specific to the grass pollen allergoid and relevant cross-reactive pollens; the mechanism does not apply to unrelated allergens.

Administration Scope

The administration of РАГВИЗАКС (Allergoids Grass Pollen) follows a fixed, long-term protocol for allergen-specific immunotherapy.

Instruction Entity	Description
Route of administration	Sublingual use only (tablet placed under the tongue).
Dosing schedule	A fixed dose of one 75,000 SQ-T tablet daily is the standard regimen for starting and maintenance treatment.
Timing in relation to meals	Consumption of food or beverage must be avoided for at least 5 minutes after taking the tablet.
Age-group administration rules	The treatment is approved for use in individuals aged 5 through 65 years.
Special procedural conditions	The first dose must be administered under medical supervision in a healthcare setting. Treatment must be paused temporarily for approximately seven days following oral surgery or the presence of oral wounds.

---

Use Protocol and Frequency

The medicine is classified as a daily treatment and must be initiated pre-seasonally, beginning approximately 12 weeks to 4 months before the expected start of the grass pollen season. A treatment course of three consecutive years is recommended for the long-term, sustained therapeutic effect.

Step sequence:

• The oral lyophilisate must be handled with dry hands before removal from the blister.
• The tablet is placed immediately under the tongue and allowed to dissolve completely.
• Swallowing must be avoided for at least 1 minute as the tablet dissolves.
• If a dose is missed, it should be taken later the same day, but patients must not take a double dose to compensate.

Research evidence / Overview of Studies for РАГВИЗАКС

---

Evidence for Use in Seasonal Allergic Rhinoconjunctivitis

Studies was studied for its use in managing seasonal allergic rhinoconjunctivitis, which is the condition involving both nose and eye symptoms caused by grass pollen. The research applied in research contexts involving fluctuating or unstable symptoms during the grass pollen season. Researchers designed large-scale randomized and placebo-controlled clinical trials, often involving hundreds of patients.

The primary focus of these pivotal studies was evaluated in measuring outcomes related to physical discomfort. Researchers studies monitored changes in patient-reported outcomes describing perceived discomfort using a composite score that tracked daily symptom severity and the consumption of symptomatic relief medications. Furthermore, the studies research examined how treatment related to the patients' overall outcomes reflecting daily functioning or activity level. Some trials reported outcomes where the observed combined score measurements was observed in some studies compared to placebo, tracking how symptoms were recorded in the observed populations during the grass pollen season.

However, data show patterns related to the absolute difference in composite score measurements compared to placebo was characterized in the regulatory assessment documentation. This means that while trials research describes group patterns, the findings do not determine whether an individual will respond similarly.

Long-Term Studies and Durability of Effect

Long-term observation periods were documented in the research. Studies observing long-term outcomes tracked treatment periods of three consecutive years, followed by extended observation. Evidence tracking post-treatment periods describes patterns that were monitored following the conclusion of the three-year course. What remains uncertain is the long-term changes in the underlying allergic condition. Research has also explored adherence, noting that follow-up durations were limited in some real-world settings that tracked multi-year use, which impacts the certainty of long-term findings.

Research in Special Study Populations

РАГВИЗАКС was evaluated in specific groups, including both adults and children (from age 5 years and older), and patients with co-existing mild asthma. Research was studied for the pediatric population, and studies explored the measurements of change in reported symptoms compared to adult trials. Study results described similar patterns between the children and adult groups. While these groups was observed in the trials, results apply only to the populations studied, and data for certain specific age groups or for patients with complex medical histories remain limited.

Key Studies & References

1. Grazax Grazura oral lyophilisate - Utredningsrapport (European Public Assessment Report Summary)
2. The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 GRAZAX 75 000 SQ-T (Pediatric and Duration Review)

Common questions about РАГВИЗАКС (FAQ)

Q: Does РАГВИЗАКС interact with other common medications?

A: Official product information addresses specific drug classes that may interact with the medicine, particularly concerning its effect on emergency epinephrine (adrenaline). These include certain substances like beta-blockers and specific antidepressants. The official product information notes the importance of discussing all current medicines with a healthcare provider.

Q: How long until I start feeling the full benefits of the treatment?

A: Studies and official information indicate that this is a long-term treatment intended to modify the disease course over time. Clinical benefits are typically expected to begin appearing after a few months of daily use. The full recommended treatment course of three consecutive years is studied for achieving the long-term, sustained therapeutic effect.

Q: What are the most common side effects of the tablet?

A: According to official regulatory documents, the most common side effects (Very Common, affecting 1 in 10 people or more) are generally localized to the mouth and throat. These frequently include oral itching (pruritus), throat irritation, and swelling of the mouth or lips. These localized reactions are most often reported during the initial weeks of treatment.

Q: What should I do if I get an allergic reaction or side effect?

A: Official patient counseling information discusses stopping the medicine and seeking immediate medical attention if symptoms of a serious allergic reaction occur, such as difficulty breathing. The official label suggests consulting a healthcare provider if mouth symptoms or irritation become severe, painful, or persistent.

Q: Can I take the tablet with water or any liquid?

A: The tablet is an oral lyophilisate that must be placed immediately under the tongue and allowed to dissolve completely. The product is designed to dissolve under the tongue for at least 1 minute before swallowing. Consumption of food or drink is avoided for at least 5 minutes after taking the medicine to ensure proper absorption.

Q: Does the tablet have to be refrigerated?

A: Official storage instructions state that the medicine does not require refrigeration. It must be kept at room temperature in the original blister pack and carton, and protected from moisture.

Q: Can I stop taking the medicine if my symptoms go away?

A: The medicine is designed as a disease-modifying treatment requiring sustained exposure over a period of time. The recommended duration of treatment is three consecutive years. Regulatory documents indicate that the duration of treatment is determined by the healthcare provider to achieve the best long-term outcome.

Q: Does this medicine treat non-grass pollen allergies (like ragweed or tree pollen)?

A: According to the official Indications section, this medicine is designed and approved only for the treatment of allergies specifically caused by grass pollen. Its mechanism of action is strictly specific to the grass pollen allergoid and does not apply to unrelated allergens like ragweed or tree pollen.

Q: What are the ingredients other than the active one (inactive ingredients)?

A: Official labeling documents contain a full and complete list of all inactive ingredients, which are also known as excipients. This information is included as the medicine is contraindicated for use in patients with a known hypersensitivity to any of the listed excipients.

How to Store and Dispose of РАГВИЗАКС?

The storage and disposal of this medicine are governed by official regulatory requirements to maintain product integrity and environmental safety.

Storage Requirements

Storage Condition	Requirement
Temperature	Does not require special temperature conditions (store at room temperature).
Protection	Must be kept in the original blister pack and outer carton to protect the lyophilisate from moisture.
Prohibited	The medicine must not be used after the expiry date printed on the packaging.
Child Safety	Must be kept out of the sight and reach of children.

️ Disposal Instructions

Unused or expired РАГВИЗАКС must not be disposed of via household waste or wastewater. The official instruction is to return the medicine to a pharmacist or designated collection point for appropriate pharmaceutical waste handling.